Remote Ischemic Conditioning for Anthracycline Cardiotoxicity: The Need to Protect the Most Vulnerable
(se abrirá en una nueva ventana)
Autores:
Ibáñez B, Gomes-Silva M, et al.
Publicado en:
J Am Coll Cardiol CardioOnc, 2023, Página(s) 356-359, ISSN 2666-0873
Editor:
NewYork: Elsevier
DOI:
10.1016/j.jaccao.2023.05.002
The quest for the mechanism responsible for the cardiovascular benefits of novel antidiabetic agents
(se abrirá en una nueva ventana)
Autores:
Danielle Medina-Hernándeza, Carlos Galán-Arriola, and Borja Ibáñez
Publicado en:
REC: CardioClinics, 2023, ISSN 2605-1532
Editor:
Elsevier
DOI:
10.1016/j.rccl.2022.09.002
Rationale and design of <scp>RESILIENCE</scp>: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity
(se abrirá en una nueva ventana)
Autores:
Andrea Moreno‐Arciniegas, Alberto García, Malte Kelm, Francesco D'Amore, María Gomes da Silva, Javier Sánchez‐González, Pedro L. Sánchez, Teresa López‐Fernández, Raul Córdoba, Riccardo Asteggiano, Vincent Camus, Jouke Smink, Antonio Ferreira, Marie J. Kersten, Natacha Bolaños, Noemi Escalera, Elsa Pacella, Sandra Gómez‐Talavera, Antonio Quesada, Xavier Rosselló, Borja Ibanez, nu
Publicado en:
European Journal of Heart Failure, 2024, ISSN 1388-9842
Editor:
Elsevier BV
DOI:
10.1002/ejhf.3395
The Quest for an Early Marker of Anthracycline-Induced Cardiotoxicity
(se abrirá en una nueva ventana)
Autores:
Borja Ibanez, and Andrea Moreno-Arciniegas
Publicado en:
JACC: Basic to Translational Science, 2022, ISSN 2452-302X
Editor:
ScienceDirect
DOI:
10.1016/j.jacbts.2021.11.010